Search the Newsreel

Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Elicio Therapeutics announced its second-quarter 2026 financial results and provided corporate updates, including plans to initiate a Phase 1 combination study of ELI-002 7P for metastatic pancreatic cancer in Q4 2026, following observations of multiple complete responses. While its Phase 2 AMPLIFY-7P trial did …

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics has announced the activation of an investigator-initiated Phase 1 study for its immunotherapy ELI-002 7P, targeting KRAS-driven pancreatic ductal adenocarcinoma (PDAC) in the neoadjuvant setting. The study, conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation and Break …

Elicio Study to Test Immunotherapy Before Pancreatic Cancer Surgery

Elicio Therapeutics has activated an investigator-initiated Phase 1 study to evaluate its immunotherapy ELI-002 7P in patients with resectable and borderline resectable KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). The study, conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation and Break …

Certain Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026.

Elicio Therapeutics, Inc. has certain warrants under a lock-up agreement that ends on August 6, 2026. The lock-up period for these warrants began on July 6, 2026, and lasts for 31 days. This agreement restricts officers and directors from selling or disposing of common …

Elicio Therapeutics, Inc. (NASDAQ:ELTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Elicio Therapeutics (ELTX) Expected to Post Earnings on Thursday

Elicio Therapeutics Inc (ELTX) Institutional Confidence

The article reports on Elicio Therapeutics Inc.'s (ELTX) institutional confidence score, which stands at 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 37.43% quarter-over-quarter, reaching 15.12%. James Simons is noted as the …

Price to sales ratio of Elicio Therapeutics, Inc – HAM:9HA

This article provides financial information for Elicio Therapeutics, Inc (HAM:9HA), specifically focusing on its price to sales ratio. The content lists the company's trading information on the Hamburg Stock Exchange and indicates that no trades have occurred for the period. It also details the …

Elicio Therapeutics Inc (ELTX) Cash Flow

This article provides a detailed cash flow statement for Elicio Therapeutics Inc (ELTX), including quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, capital expenditures, and changes in working capital across multiple fiscal years. The …

Working capital per share of Elicio Therapeutics, Inc – HAM:9HA

This article provides working capital per share data for Elicio Therapeutics, Inc (HAM:9HA) on the Hamburg Stock Exchange. The market was closed at the time of publication, with no trades recorded. The content is presented as part of TradingView's financial data offerings.

Elicio Therapeutics Inc (ELTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Elicio Therapeutics Inc (ELTX). It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides current stock information for ELTX, including its market cap …

Elicio Therapeutics Inc (ELTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Elicio Therapeutics Inc (ELTX) shareholder structure, listing major shareholders and institutional holdings. It highlights key entities like GKCC, LLC and Knoll Capital Management, LLC, their proportions, and also categorized shareholder types. The report also tracks changes in …

ELTX|Elicio Therapeutics Inc|Price:3.000|Chg%:-0.150

Elicio Therapeutics Inc (ELTX) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, specifically targeting mutant KRAS, BRAF, and TP53. Despite a recent weak market performance, the company exhibits strong fundamentals and technicals and is considered fairly valued. Analysts have given it …

Form 4 Elicio Therapeutics Inc For: 17 July By Investing.com

This Investing.com article reports on a Form 4 filing for Elicio Therapeutics Inc. on July 17. The Form 4 is a U.S. Securities and Exchange Commission document used to report changes in beneficial ownership of a company's stock by insiders. The article indicates that …

Elicio Therapeutics (ELTX) awards 60,833 stock options to its CFO

Elicio Therapeutics, Inc. (ELTX) has granted its Chief Strategy and Financial Officer, Preetam Shah, 60,833 stock options at an exercise price of $3.20 per share, as detailed in a Form 4 SEC filing. These options expire on July 16, 2036, and will vest in …

Elicio Therapeutics (ELTX) awards 64,643 stock options to R&D and medical chief

Elicio Therapeutics (ELTX) has granted 64,643 stock options to Christopher Haqq, Executive Vice President, Head of R&D, and Chief Medical Officer. The options have an exercise price of $3.20 per share, expire on July 16, 2036, and vest in two 50% tranches on July …

Elicio Therapeutics (ELTX) grants 52,832 stock options to Chief Scientific Officer

Elicio Therapeutics, Inc. (ELTX) has granted 52,832 stock options to its Chief Scientific Officer, Peter DeMuth. The options have an exercise price of $3.20 per share and will expire on July 16, 2036. The shares will vest in two equal installments, 50% on July …

Elicio Therapeutics (ELTX) CEO awarded 186,944 stock options at 3.2000

Elicio Therapeutics (ELTX) CEO, President, and Director Robert Connelly was granted 186,944 stock options at an exercise price of $3.20 per share on July 16, 2026. These options expire on July 16, 2036, and vest in two equal tranches on July 16, 2027, and …

Moti Investments discloses 6.1% stake in Elicio Therapeutics (NASDAQ: ELTX)

Moti Investments LLC has disclosed a 6.1% stake in Elicio Therapeutics, owning 1,408,892 shares of common stock, as reported in a Schedule 13G filing. The investment firm, organized in Saint Kitts and Nevis and based in Dubai, holds sole voting and dispositive power over …

ELTX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical Development - Earnings Power Value

ELTX Forecast — Price Target — Prediction for 2027

Elicio Therapeutics (ELTX) Drops 4.14% as Bearish Momentum Tests Key Support - Quality ETF

Elicio Therapeutics Inc. (NASDAQ: ELTX) Stock Price, News & Analysis

Elicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)

Elicio Therapeutics, Inc. 1Q 2026: Net income $(11.8M), EPS $(0.65) — 10-Q Summary

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownership

Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Elicio Therapeutics Inc. (ELTX) Live Share Price, Invest From India

Elicio Therapeutics, Inc. (ELTX) Stock Price, News, Quote & History